Capricor Therapeutics (CAPR) Cash from Operations (2010 - 2026)

Capricor Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 29254891.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 354.73% year-over-year to 29254891.0; the TTM figure through Mar 2026 stood at 92632632.0 (down 105.12% YoY), while the FY2025 annual figure was 69811261.0, down 74.55% from the prior year.
• Cash from Operations was 29254891.0 for Q1 2026 at Capricor Therapeutics, down from 23566743.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 24046566.0 in Q1 2022 to a low of 29254891.0 in Q1 2026.
• Historically, Cash from Operations has averaged 9396576.59 across 5 years, with a median of 9417750.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations soared 822.26% in 2022, then plunged 407.2% in 2025.
• A 5-year view of Cash from Operations shows it stood at 6902052.0 in 2022, then sank by 67.98% to 11594052.0 in 2023, then dropped by 27.62% to 14796329.0 in 2024, then plunged by 59.27% to 23566743.0 in 2025, then dropped by 24.14% to 29254891.0 in 2026.
• The last three Cash from Operations figures came in at 29254891.0 (Q1 2026), 23566743.0 (Q4 2025), and 19688787.0 (Q3 2025), per Business Quant data.